肺癌患者GSTM1基因型与p53基因突变的相关关系研究

Combined Analysis of Polymorphisms of GSTM1 and Mutations of p53 Gene in The Patients with Lung Cancer

目的:探索肺癌患者Ⅱ相代谢酶主要亚型GSTM1的基因型与p53基因突变的关系。方法:应用双重PCR和PCR-SSCP(单链构像多态性分析)技术,检测了63例肺癌患者和47例健康对照中GSTM1基因缺失及肺癌组织p53基因突变的情况,并分析其相关关系。结果:肺癌组GSTM1基因缺失率为71.4%(45/63),对照组为51.1%(24/47),差异有显著统计学意义,OR为2.40(95%CI为1.09-5.29)。p53基因突变率在63例肺癌组织中为49.2%(31/63),在15例对照组织中仅为6.6%(1/18)。58.1%肺癌病例同时存在p53基因突变和缺失GSTM1基因(P<0.05)。结论:GSTM1基因缺失与p53基因突变相关,GSTM1基因缺失可能增加p53基因突变的几率,从而导致肺癌患病危险性的增加。

s Objective: The aim of this study was to analyze the association of phase Ⅱ metabolism glutathione S-transferase mu gene (GSTM1) and mutations of p53 gene in the patients with lung cancer. Methods: GSTM1 polymorphisms were determined by the multi-differential polymerase chain reaction(MD-PCR) method. The polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) was performed for detection of point mutations at exons 5-8 of the p53 gene. Results: The deletion (null phenotype) rate of GSTM1 in lung cancer patients was significantly higher than that in control groups, 71.4% (45/63) and 51.1% (24/47), respectively. The odds ratio associated with GSTM1 null genotype was 2.40 (95% confidence interval 1.09, 2.59). Lung cancer patients showed a higher rate (49.2%, 31/63) of p53 gene mutation than the control group (6.6%, 1/15) and 58.1% (18/31) of lung cancer patients showed the combined deletion of GSTM1. Conclusion: We conclude that GSTM1 deletion associates with p53 gene mutation in lung cancer. GSTM1 deletion increased the risk of lung cancer appears to be mediated through the mechanisms to p53 expression.